For research and educational purposes only. Not medical advice.
Direct Answer
Cyanocobalamin is the synthetic, highly stable form of B12 used in most standard injections and fortified foods. It requires the body to convert it before use, which works fine for healthy people but less well for those with methylation or absorption issues. Methylcobalamin is the naturally occurring, bioactive form that the body can use immediately, with the strongest documented advantage in neurological applications like peripheral neuropathy. MIC B12 is a compounded formulation that combines methionine, inositol, and choline (lipotropic compounds) with B12, marketed as a "skinny shot": the evidence for it as a standalone weight-loss treatment is weak, but it has more legitimate support as an adjunct to a physician-supervised weight management program.
Walk into any functional medicine clinic, weight loss practice, medical spa, or compounding pharmacy in 2026 and readers will encounter at least two or three different formulations of vitamin B12 being offered for injection. Methylcobalamin. Cyanocobalamin. MIC B12. Lipo-B. Lipo-Mino. The alphabet soup of B12 formulations has grown considerably over the past decade, and the marketing language around each one has not always helped people understand what they are actually getting.
This guide cuts through the confusion. We are going to cover what vitamin B12 actually is and what it does in the body, the fundamental chemical differences between methylcobalamin and cyanocobalamin and why those differences matter clinically, what MIC B12 is and how it differs from a standalone B12 injection, what the research actually supports for each formulation, and how to think about which one makes sense for which person and which goal.
This is not a supplement advertisement. It is a complete, evidence-grounded breakdown of the most commonly confused nutrient formulations in the functional medicine and biohacking space.
What Vitamin B12 Actually Is and Why It Matters
Vitamin B12, chemically known as cobalamin, is a water-soluble vitamin with one of the most complex molecular structures of any vitamin the human body requires. At the center of that structure sits a cobalt atom, which is where the cobalamin name originates. That cobalt atom is surrounded by a corrin ring structure and, critically, has an attachment point where different chemical groups can bind. The specific group attached to that cobalt atom is what differentiates the various forms of B12 from one another.
Why does the body need B12 in the first place? The answer is that B12 is not a single-purpose micronutrient. It functions as a coenzyme in at least two critically important metabolic pathways.
The first is the methionine synthase pathway. This enzyme uses methylcobalamin, the methyl-group-bearing form of B12, to convert homocysteine back to methionine. This is not a trivial reaction. Methionine is the precursor to S-adenosylmethionine (SAMe), the primary methyl donor in the body used for DNA methylation, neurotransmitter synthesis, phospholipid production, and gene expression regulation. When this pathway is impaired by B12 deficiency, homocysteine accumulates. Elevated homocysteine is an independent cardiovascular risk marker.
The second pathway involves methylmalonyl-CoA mutase, an enzyme that uses adenosylcobalamin (a different active form of B12) to convert methylmalonyl-CoA to succinyl-CoA in mitochondrial energy metabolism. When this pathway is impaired, methylmalonic acid accumulates, which is a specific and sensitive marker for functional B12 deficiency.
These two pathways explain why B12 deficiency produces such a wide range of clinical consequences: megaloblastic anemia from impaired DNA synthesis, peripheral neuropathy and subacute combined degeneration of the spinal cord from impaired myelin production, cognitive decline and depression from impaired neurotransmitter synthesis, and cardiovascular risk from accumulated homocysteine.
The body cannot synthesize B12 endogenously. It must come from dietary sources, primarily animal products, or supplementation. This makes it one of the most genuinely essential nutrients in human physiology, and getting the form right matters more than many people realize.
Cyanocobalamin: The Synthetic Standard
Cyanocobalamin is the form of B12 most commonly found in inexpensive oral supplements, fortified foods, and standard pharmaceutical B12 injections. Its name reflects its chemistry: the cobalt atom in cyanocobalamin has a cyanide group (CN) attached at the active site.
The word cyanide predictably generates alarm in anyone who encounters this information for the first time. The clinical reality is that the cyanide content of a standard cyanocobalamin supplement dose is pharmacologically trivial. A typical cyanocobalamin injection contains approximately 1,000 micrograms of B12, of which the cyanide component represents roughly 20 micrograms. For reference, a single serving of spinach or almonds contains more cyanogenic compounds than a cyanocobalamin injection. This is not a meaningful safety concern for the general population.
What makes cyanocobalamin the dominant form in standard pharmaceutical practice is not its metabolic superiority. It is its physical properties. Cyanocobalamin is exceptionally stable. It does not degrade when exposed to light, does not require refrigeration under normal storage conditions, and has a shelf life measured in years rather than weeks. This stability makes it ideal for mass production, food fortification, and standard supplement manufacturing where product consistency across long supply chains matters.
The metabolic trade-off is that cyanocobalamin is not biologically active. The body cannot use it directly. Before cyanocobalamin can participate in either of the two B12-dependent metabolic pathways, the cyanide group must be removed and replaced with either a methyl group (producing methylcobalamin for the methionine synthase pathway) or an adenosyl group (producing adenosylcobalamin for the methylmalonyl-CoA mutase pathway). This conversion process requires adequate enzyme activity and metabolic capacity in the liver and other tissues.
For healthy individuals with normal enzyme activity, this conversion proceeds efficiently and cyanocobalamin supplementation effectively raises B12 status and corrects deficiency. The research on cyanocobalamin for treating B12 deficiency is extensive and demonstrates clear effectiveness at standard doses. One comparison study found absorption of approximately 49% for cyanocobalamin versus 44% for methylcobalamin at the same dose, suggesting that at the point of initial absorption alone, the two forms perform comparably.
Where cyanocobalamin falls short is in specific populations. Individuals with MTHFR gene mutations affecting methylation efficiency, older adults with reduced gastric acid production impairing intrinsic factor function, people taking metformin or proton pump inhibitors that reduce B12 absorption, and anyone with conditions affecting hepatic conversion capacity may not convert cyanocobalamin to active forms as efficiently as younger healthy individuals. For these populations, receiving an already-active form of B12 removes a conversion step that may be functionally impaired.
Methylcobalamin: The Bioactive Form
Methylcobalamin is the form of B12 that has a methyl group (CH3) attached to the cobalt atom. It is naturally occurring, found in animal-based foods and present in human blood and cerebrospinal fluid. It is one of the two bioactive coenzyme forms of B12, meaning it can be used directly by the body's enzymes without requiring conversion from an inactive precursor.
The critical implication is that methylcobalamin enters the methionine synthase pathway immediately upon delivery to tissue. There is no conversion step, no dependence on enzyme function, no cyanide to detoxify, and no metabolic overhead between administration and biological availability. This makes it inherently more efficient for populations with impaired conversion capacity and potentially more rapidly effective even in healthy individuals with normal conversion pathways.
The neurological applications are where methylcobalamin's advantages over cyanocobalamin are most clearly documented in the research. Multiple human studies have demonstrated that methylcobalamin produces superior outcomes in peripheral neuropathy compared to cyanocobalamin. Research in diabetic neuropathy patients specifically showed that injectable methylcobalamin improved nerve conduction velocity and reduced neuropathic pain symptoms more effectively than cyanocobalamin at equivalent doses.
The mechanism behind methylcobalamin's neurological superiority makes physiological sense. The peripheral and central nervous system have uniquely high demands for methylation activity, myelin synthesis, and the neurotransmitter production that depends on SAMe. Delivering an already-active methyl donor directly to the nervous system tissue bypasses the conversion bottleneck that can limit cyanocobalamin's effectiveness specifically in neural applications.
The primary trade-off is stability. Methylcobalamin is significantly more light-sensitive than cyanocobalamin. It degrades rapidly when exposed to UV or even normal fluorescent lighting and requires amber vials, foil packaging, or refrigerated dark storage to maintain potency over time. This instability makes it less suitable for food fortification and more expensive to manufacture, package, and store correctly. Injectable methylcobalamin must be kept refrigerated, protected from light, and used within a defined window after preparation.
For injections specifically, the light-stability issue is worth taking seriously. A methylcobalamin vial that has been sitting on a clinic counter under fluorescent lighting for extended periods may have degraded meaningfully before it ever reaches the patient. This is not a theoretical concern. It is a practical reason why sourcing from compounding pharmacies with documented quality controls and proper storage protocols matters for methylcobalamin specifically.
A 2025 comprehensive review published in Cureus examining natural versus synthetic forms of B12 consumption and supplementation concluded that methylcobalamin appears more consistently effective and bioavailable, and may be preferable for individuals with impaired absorption or methylation pathways. The paper also noted that future research should clarify long-term outcomes in high-risk groups, acknowledging that while the mechanistic advantage of methylcobalamin is well-established, large-scale long-term outcome data is still developing.
Hydroxocobalamin: The Third Form Worth Knowing
Before moving to MIC B12, hydroxocobalamin deserves a brief mention because it appears in clinical settings frequently enough to cause confusion.
Hydroxocobalamin has a hydroxyl group (OH) attached to the cobalt atom. It is a naturally occurring form found in bacteria and animal foods, and it is the standard form used in intramuscular B12 injections in the United Kingdom and many European countries. Its key advantage over cyanocobalamin is that the body converts it to both methylcobalamin and adenosylcobalamin, the two active forms, more efficiently than it converts cyanocobalamin. It also has significantly longer tissue retention than either cyanocobalamin or methylcobalamin, which is part of why it is favored for less-frequent dosing schedules.
Hydroxocobalamin is also the standard treatment for cyanide poisoning because it binds circulating cyanide to form cyanocobalamin, which is then safely excreted. This mechanism is precisely why it is contraindicated in the same patients who should avoid cyanocobalamin.
In the US compounding pharmacy market, hydroxocobalamin appears in some MIC formulations and standalone injection protocols. Its longer retention and efficient conversion to both active forms make it a clinically sound choice for general B12 repletion, though it lacks the direct neural bioavailability advantage that methylcobalamin provides.
MIC B12: What It Is, What Each Component Does, and What the Research Says
MIC B12 is a compounded injection formulation that combines three lipotropic compounds, methionine, inositol, and choline, with vitamin B12, typically methylcobalamin or cyanocobalamin depending on the compounding pharmacy's formulation choice. The term lipotropic refers to substances that promote the breakdown and transport of fat, particularly in the liver.
MIC B12 is not a pharmaceutical compound. It is a compounded formulation prepared by licensed 503A compounding pharmacies, typically used in physician-supervised weight management programs, metabolic health protocols, and functional medicine practices. It is sometimes called the "skinny shot," a marketing label that oversimplifies what the injection actually does and overstates the weight loss evidence, which is addressed directly below.
Methionine
Methionine is an essential amino acid, meaning the human body cannot synthesize it and must obtain it through diet or supplementation. In the context of MIC injections, methionine serves two primary functions.
First, it participates directly in fat metabolism through the methylation cycle. Methionine is converted to SAMe, which donates methyl groups across hundreds of biochemical reactions including phosphatidylcholine synthesis, which is required for the production of VLDL particles that transport fat out of the liver. When methionine is adequate, this phospholipid export mechanism works efficiently and fat does not accumulate in the liver.
Second, methionine is involved in glutathione synthesis, the body's primary endogenous antioxidant. Adequate methionine status supports the cysteine availability that glutathione production requires.
The injectable delivery bypasses gastrointestinal absorption variability and delivers methionine directly to systemic circulation, achieving tissue concentrations that oral supplementation may not reliably produce in individuals with compromised digestive function.
Inositol
Inositol is a naturally occurring carbohydrate sometimes classified informally as a B-vitamin, though it does not fit the strict definition of an essential vitamin because the body can synthesize it. It exists in multiple isomer forms, with myo-inositol being the most biologically active and the form present in MIC injections.
Inositol's role in fat metabolism operates through its position as a component of phosphatidylinositol, a phospholipid that participates in cellular signaling pathways including insulin receptor signaling and VLDL particle assembly for hepatic fat export. Beyond fat metabolism, inositol is a precursor to second messengers involved in serotonin and dopamine receptor signaling, which creates its documented relationship to mood regulation, appetite control, and cognitive function.
Human research on inositol supplementation has demonstrated clinically meaningful effects in polycystic ovarian syndrome (PCOS) through improvement of insulin sensitivity, in anxiety disorders at higher oral doses (12 to 18 grams per day in some trials), and in obsessive-compulsive disorder. The MIC injection dose of inositol is considerably lower than the doses used in these psychiatric trials, so direct extrapolation of the mental health data to MIC injection effects should be made cautiously.
Choline
Choline is an essential nutrient required for phosphatidylcholine synthesis, acetylcholine neurotransmitter production, and lipid transport. Its role in the MIC formulation centers on its function in hepatic fat export: phosphatidylcholine is the primary phospholipid component of VLDL particles, and adequate choline availability is required for the liver to package and export triglycerides into circulation rather than allowing them to accumulate as hepatic fat.
Choline deficiency is well-documented to produce non-alcoholic fatty liver disease (NAFLD) in animal models and in humans maintained on choline-deficient diets in controlled research settings. Restoring choline corrects this fat accumulation. The question of whether supraphysiological choline injection in individuals who are not choline-deficient produces meaningful additional fat mobilization is the critical gap in the MIC evidence base, discussed below.
The Vitamin B12 Component in MIC
The B12 in MIC injections serves the same functions described throughout this post, with the additional context that the lipotropic compounds in the MIC formulation are themselves methylation-dependent for their activity. Methionine's conversion to SAMe requires methylcobalamin. The phospholipid synthesis pathways that choline and inositol support are influenced by methylation status. The B12 component is therefore not merely a co-injection for energy but a mechanistically relevant partner to the lipotropic compounds in the formulation.
Most quality compounding pharmacies now use methylcobalamin rather than cyanocobalamin in MIC formulations, specifically because the methylation-dependent nature of the lipotropic pathways makes the bioactive form more synergistic. When evaluating MIC injection sources, verifying which form of B12 is in the formulation is worth confirming explicitly.
What the Research Actually Supports for MIC B12
Here is where intellectual honesty requires a direct statement: the clinical evidence base for MIC injections as a weight loss intervention is limited and lower quality than most of the marketing around them implies.
No large randomized controlled trial has established MIC injection as an effective standalone weight loss therapy. The published evidence for weight loss from MIC specifically rests primarily on small studies, observational data, and programs that combine MIC injections with caloric restriction, dietary changes, and exercise, making it impossible to isolate the contribution of the injection from the broader lifestyle intervention.
Medical News Today states clearly that "researchers have not confirmed the effectiveness of lipotropic injections" and that "research has not confirmed that taking doses of vitamin B12 or methionine above the recommended amount helps a person lose weight." Healthline similarly notes that "limited research exists on their efficacy" for weight loss specifically.
This does not mean MIC injections have no biological basis or no clinical utility. The biology underlying each individual component is real and well-established. Methionine, inositol, and choline all genuinely participate in fat metabolism pathways in the ways described above. The question is whether injecting these compounds into people who are not specifically deficient in them produces pharmacologically meaningful additional fat mobilization beyond what a well-composed diet would produce. That question has not been definitively answered by the current published evidence.
Where MIC injections have stronger evidentiary support is as adjunct therapy in physician-supervised programs combining caloric restriction with exercise and nutritional support. In this context, the combination appears to provide metabolic support for liver function, phospholipid synthesis, and energy during the increased metabolic demands of a weight loss program, with the B12 component specifically contributing to energy metabolism and red blood cell production that can be challenged during caloric restriction.
The practical implication: MIC B12 is most defensible as a supportive component of a structured, physician-supervised weight management program rather than as a standalone fat-burning injection. Clinicians who position it honestly in this role are serving their patients well. Clinics that market it as a standalone weight loss solution are overstating what the evidence supports.
Head-to-Head: How to Think About Each Formulation
Cyanocobalamin injection makes sense as the cost-effective choice for straightforward B12 deficiency correction in healthy individuals with normal conversion capacity, normal gastric function, and no significant methylation concerns. It is stable, inexpensive, and effective for the core clinical indication of B12 repletion.
Methylcobalamin injection is the better clinical choice for individuals with neurological symptoms, peripheral neuropathy, cognitive concerns, depression, sleep disruption, MTHFR gene mutation status, impaired gastric acid production (including those on proton pump inhibitors or metformin), older adults, or anyone where methylation pathway efficiency is a clinical concern. The premium in cost and storage requirements is justified by the direct bioavailability advantage in these populations.
MIC B12 injection with methylcobalamin is the appropriate formulation for physician-supervised weight management and metabolic support programs where hepatic fat metabolism, lipid transport, and energy metabolism support are clinical goals alongside B12 repletion. It is not appropriate as a standalone weight loss solution or as a replacement for dietary adequacy and lifestyle modification.
The formulation choice matters. So does the quality of the compounding pharmacy preparing it.
Why Sourcing and Quality Matter for Injectable B12 Formulations
Every injectable B12 formulation described in this post is a compounded product prepared by a licensed 503A compounding pharmacy. As with all compounded injectables, the quality of the final product depends entirely on the manufacturing standards, raw material quality, sterility protocols, and testing practices of the compounding facility preparing it.
Methylcobalamin's light sensitivity means that a vial prepared with inadequate light protection, stored improperly, or shipped without temperature control may have significantly lower potency than the label claims. MIC formulations combine multiple active compounds in a single vial, meaning each individual component must be within specification for the formulation to deliver its intended effect. A COA from the compounding pharmacy confirming potency, sterility, and endotoxin compliance for the specific batch is the minimum quality documentation worth requiring for any injectable formulation.
This is the same standard that applies to every other compounded injectable product in the research and functional medicine space. The compound is only as good as the quality infrastructure behind it.
For vetted vendors, current coupon codes, and active sale information, visit RUO Codes' vendor directory. Details of an active vendor promotion appear on the Active Sales tab.
The Bottom Line
Vitamin B12 is genuinely essential and genuinely important. The form readers receive matters in specific clinical contexts, particularly for neurological applications and populations with impaired conversion capacity. Methylcobalamin is the more physiologically direct choice for most injection applications and is increasingly the standard in quality functional medicine practice. Cyanocobalamin remains a clinically effective and cost-efficient option for basic deficiency correction in healthy adults. MIC B12 provides a compounded formulation targeting fat metabolism and metabolic support alongside B12 repletion, with a clinical evidence base that best supports its use as adjunct therapy in structured weight management programs rather than standalone fat burning.
None of these formulations are magic. All of them work through documented and well-characterized biological pathways. The gap between what each compound actually does and how it is sometimes marketed is the most important consideration before a clinical or personal decision about which one is the right choice.
For research and educational purposes only. Not medical advice. Always consult a qualified healthcare provider before initiating any injectable therapy.